Bio-Works Technologies (BIOWKS) Q1 2025 earnings summary

Executive summary

• Order intake reached a record SEK 31.6 million in Q1 2025, with strong growth in Europe and positive trends in the USA and Asia.

• Net sales increased to SEK 9.0 million from SEK 5.9 million year-over-year, driven by large deliveries in Europe and the USA.

• Operating loss improved to SEK -7.8 million from SEK -12.2 million, reflecting cost reductions and improved gross margin.

• Profit for the quarter was SEK -8.0 million, an improvement from SEK -11.8 million in Q1 2024.

• Cash and cash equivalents at period end were SEK 29.7 million, up from SEK 27.3 million a year earlier.

Financial highlights

• Order intake: SEK 31.6 million (Q1 2024: SEK 6.2 million).

• Net sales: SEK 9.0 million (Q1 2024: SEK 5.9 million).

• Operating profit/loss: SEK -7.8 million (Q1 2024: SEK -12.2 million).

• Earnings per share: SEK -0.10 (Q1 2024: SEK -0.30), before and after dilution.

• Cash flow from operating activities: SEK -4.4 million (Q1 2024: SEK -12.3 million).

Outlook and guidance

• Strong order pipeline and continued growth in order intake beyond Q1, with SEK 14.4 million in new orders in April.

• Focus on scaling production, streamlining operations, and maintaining cost control to support future growth.